跳到正文
FDA 官方药品与生物制品信息·AI 评分39

FDA 抗菌药物药敏试验标准更新通知(含阿米卡星、阿莫西林克拉维酸等)

Notices of Updates

AI 导读

FDA 发布抗菌药物药敏试验标准更新通知,涉及阿米卡星、阿莫西林克拉维酸、阿奇霉素、氨曲南阿维巴坦等多种药品。更新内容包括对肠杆菌目、铜绿假单胞菌等菌种认可或取消认可 M100 标准(MIC 与纸片扩散法),以及识别或更新 STIC。各条目均标注具体更新日期,最早可追溯至 2020 年。

正文 · 原文

AmikacinInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa. Rationale Antibacterial10/22/2025AmikacinInjectionFDA does not recognize M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosaAntibacterial4/21/2023Amoxicillin and clavulanateOralFDA recognizes M100 standard (MIC) for Haemophilus influenzae. Rationale Antibacterial5/15/2025Amoxicillin and clavulanateOralFDA does not recognize M100 standard and provides STIC for Haemophilus influenzae.Antibacterial5/17/2022AzithromycinOral, InjectionFDA identified STIC (disk diffusion) for Neisseria gonorrhoeae. Rationale Antibacterial5/29/2026AzithromycinOral, InjectionFDA identified STIC (MIC) for Neisseria gonorrhoeae. RationaleAntibacterial1/16/2025AzithromycinOral, InjectionFor Neisseria gonorrhoeae, FDA has reviewed STIC and concludes no changes are needed at this time. RationaleAntibacterial10/14/2021Aztreonam and avibactamInjectionFDA recognizes M100 standard (disk diffusion) for Enterobacterales.Antibacterial2/05/2026Aztreonam and avibactamInjectionFDA identified STIC (MIC and disk diffusion) for Enterobacterales.Antibacterial2/07/2025CefadroxilOralFDA removed the statement “Susceptibility of Enterobacteriaceae to cefadroxil may be deduced from testing cefazolin.” RationaleAntibacterial4/27/2022CefazolinInjectionFDA does not recognize M100 standard for cefazolin as a surrogate to predict susceptibility of oral cephalosporins when used for the treatment of uncomplicated UTI caused by Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. RationaleAntibacterial10/20/2022CefazolinInjectionFor Enterobacterales, FDA has reviewed STIC and the updated standard is recognized. RationaleAntibacterial10/14/2021CefepimeInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Pseudomonas aeruginosaAntibacterial1/16/2025CefepimeInjectionFDA recognizes M100 susceptible-dose dependent standard (MIC and disk diffusion) for EnterobacteralesAntibacterial6/21/2023Cefepime and EnmetazobactamInjectionFDA identified STIC (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa.Antibacterial2/22/2024Cefepime and ZidebactamInjectionFDA identified STIC (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa.Antibacterial5/29/2026CefiderocolInjectionFDA recognizes M100 MIC standard and identifies disk diffusion STIC for Stenotrophomonas maltophilia. RationaleAntibacterial11/12/2024CefiderocolInjectionFDA recognizes M100 (disk diffusion) standards for Enterobacterales.Antibacterial1/31/2023CefiderocolInjectionFDA recognizes M100 MIC standard for Enterobacteriaceae.Antibacterial10/14/2021CefiderocolInjectionFDA has updated STIC and added STIC for Acinetobacter baumannii complex.Antibacterial9/25/2020CefoxitinInjectionFDA recognizes M100 standard for Staphylococcus aureus complex and Staphylococcus lugdunensis; FDA recognizes M100 disk diffusion standard for Staphylococcus epidermidis and other Staphylococcus spp.Antibacterial10/04/2022Ceftaroline fosamilInjectionFDA recognizes the M100 standard (MIC and disk diffusion) for Staphylococcus aureus. RationaleAntibacterial6/25/2024Ceftaroline fosamilInjectionFor Staphylococcus aureus, FDA has reviewed the STIC and concludes no changes are needed at this time. RationaleAntibacterial4/16/2020CeftazidimeInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Pseudomonas aeruginosaAntibacterial1/16/2025CeftazidimeInjectionFDA concurs with CLSI to remove STIC (MIC) for Stenotrophomonas maltophilia. RationaleAntibacterial5/15/2024Ceftobiprole medocaril sodiumInjectionFDA identified STIC for Staphylococcus aureus, Streptococcus pyogenes, and Enterobacterales (MIC and disk diffusion), and for Streptococcus pneumoniae, Haemophilus influenzae and Haemophilus parainfluenzae (MIC).Antibacterial4/03/2024Ceftolozane TazobactamInjectionFDA recognizes M100 standard for Haemophilus influenzae.Antibacterial10/14/2021Ceftolozane and tazobactamInjectionFDA recognizes M100 disk diffusion standard for Enterobacterales.Antibacterial5/17/2022CiprofloxacinOral, InjectionFor Salmonella spp., the updated standard is recognized.Antibacterial2/28/2020ChloramphenicolInjectionFDA does not recognize M45 standard for Abiotrophia spp., Granulicatella spp., and Aeromonas spp.Antibacterial1/16/2025ClindamycinInjection, OralFDA does not recognize M45 standard for Moraxella catarrhalisAntibacterial1/16/2025ColistimethateInjectionFDA recognizes STIC (MIC) for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp. RationaleAntibacterial2/12/2025ColistimethateInjectionFDA does not recognize M100 standard (MIC) for Enterobacterales, Pseudomonas aeruginosa, or Acinetobacter spp. RationaleAntibacterial1/17/2023DaptomycinInjectionFDA recognizes M100 standard (MIC) for Enterococcus faecium and Enterococcus spp. other than Enterococcus faecium. RationaleAntibacterial8/2/2024DaptomycinInjectionFDA updated STIC. RationaleAntibacterial8/25/2020DelafloxacinInjection, OralFDA identified STIC for Staphylococcus lugdunensis for Acute Bacterial Skin and Skin Structure Infections.Antibacterial10/06/2020FluconazoleInjection, OralFDA recognizes M27M44S susceptible-dose dependent standard (MIC and disk diffusion) for Candida spp.Antifungal8/10/2023FosfomycinInjectionFDA identified STIC (MIC and disk diffusion) for Escherichia coli and Klebsiella pneumoniae.Antibacterial 10/22/2025GentamicinInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales. FDA removed STIC for Pseudomonas aeruginosa. RationaleAntibacterial10/22/2025GentamicinInjectionFDA does not recognize M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosaAntibacterial4/21/2023GepotidacinOralFDA identified STIC (MIC and disk diffusion) for Neisseria gonorrhoeae.Antibacterial12/11/2025GepotidacinOralFDA identified STIC (MIC and disk diffusion) for Enterobacterales, Staphylococcus saprophyticus, and Enterococcus faecalis.Antibacterial3/25/2025Imipenem-Cilastatin-RelebactamInjectionFDA recognizes M100 standard for Enterobacteriaceae, Pseudomonas aeruginosa, and anaerobes.Antibacterial10/14/2021Imipenem-Cilastatin-RelebactamInjectionFDA identified STIC for Acinetobacter calcoaceticus-baumannii complex and Haemophilus influenzae.Antibacterial6/4/2020Isavuconazonium sulfate*Oral, InjectionFDA recognizes M38M51S standard for Aspergillus fumigatus. RationaleAntifungal8/22/2025LefamulinOral, InjectionFDA recognizes M100 standard (MIC and disk diffusion) for Staphylococcus aureus (methicillin-susceptible isolates), Streptococcus pneumoniae, and Haemophilus influenzae.Antibacterial2/16/2023LefamulinOral, InjectionFDA does not recognize M100 disk diffusion standard and provides STIC for Streptococcus pneumoniae and Haemophilus influenzae.Antibacterial5/17/2022LefamulinOral, InjectionFDA recognizes M100 standard for Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.Antibacterial10/14/2021LevofloxacinOral, InjectionFor Salmonella spp., the updated standard is recognized.Antibacterial2/28/2020LinezolidOral, InjectionFDA recognizes M100 (disk diffusion) standard for Staphylococcus aureus.Antibacterial5/28/2024OfloxacinOralFor Salmonella spp., the updated standard is recognized.Antibacterial2/28/2020OmadacyclineInjection, OralFDA updated disk breakpoints for Streptococcus pneumoniae for community acquired bacterial pneumonia.Antibacterial8/25/2020OxacillinInjectionFDA concurs with the revised CLSI STIC for Staphylococcus by species level. Rationale;
FDA references Cefoxitin STIC for Staphylococcus spp. as a surrogate test.Antibacterial10/04/2022PiperacillinInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales, Pseudomonas aeruginosa and Acinetobacter spp.Antibacterial9/23/2025Piperacillin and TazobactamInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Pseudomonas aeruginosa. RationaleAntibacterial1/16/2025Piperacillin and TazobactamInjectionFDA has updated STIC (MIC and disk diffusion) for Pseudomonas aeruginosa. FDA identified a susceptible-dose dependent breakpoint. FDA does not recognize M100 standard for a susceptible, intermediate, and resistance breakpoints. RationaleAntibacterial3/22/2024Piperacillin and TazobactamInjectionFDA has updated STIC (MIC and disk diffusion) for Enterobacterales. FDA has recognized M100 standard for susceptible and resistant breakpoints and updated an intermediate breakpoint. FDA does not recognize M100 standard for a susceptible dose dependent breakpoint. RationaleAntibacterial1/17/2023PivmecillinamOralFDA recognizes M100 standard (MIC and disk diffusion) for EnterobacteralesAntibacterial4/24/2024PlazomicinInjectionFDA recognizes M100 standard (MIC and disk diffusion) for EnterobacteralesAntibacterial4/21/2023Polymyxin B SulfateInjectionFDA recognizes STIC (MIC) for Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp. RationaleAntibacterial2/12/2025Polymyxin B SulfateInjectionFDA does not recognize M100 standard (MIC) for Enterobacterales, Pseudomonas aeruginosa, or Acinetobacter spp. RationaleAntibacterial1/17/2023RezafunginInjection

FDA identified STIC (MIC and disk diffusion) for Candida albicans, Candida glabrata, and Candida tropicalis.

FDA has reviewed STIC (MIC) for Candida parapsilosis, and the M27M44S standard is recognized.

FDA identified STIC (disk diffusion) for Candida parapsilosis.

Antifungal4/18/2023RifampinOral, InjectionFDA does not recognize M45 standard for HACEK group: Haemophilus spp., Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens and Kingella spp., and for Moraxella catarrhalisAntibacterial1/16/2025Sulbactam and DurlobactamInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Acinetobacter baumannii-calcoaceticus complex.Antibacterial6/06/2023Sulopenem etzadroxil and probenecidOralFDA identified STIC (MIC and disk diffusion) for Enterobacterales.Antibacterial10/25/2024Tebipenem pivoxilOralFDA identified STIC (MIC and disk diffusion) for Enterobacterales.Antibacterial6/17/2026Tedizolid phosphateOral, injectionFDA recognizes M100 (disk diffusion) standard for Staphylococcus aureus, Streptococcus spp. beta-hemolytic group, and Streptococcus spp. viridans group.Antibacterial5/28/2024TelithromycinOralFDA has removed telithromycin STIC as the drug is no longer approved in any application under section 505 of the FD&C Act (see 84 FR 47309).Antibacterial10/14/2021TobramycinInjectionFDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa. RationaleAntibacterial10/22/2025TobramycinInjectionFDA does not recognize M100 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosaAntibacterial4/21/2023VoriconazoleTablets, Powder for Oral Suspension, InjectionFDA recognizes M38M51S standard for Aspergillus fumigatus. RationaleAntifungal1/16/2025ZoliflodacinOralFDA identified STIC (MIC) for Neisseria gonorrhoeae Antibacterial12/15/2025

来源:FDA 官方药品与生物制品信息 · fda.gov